Senior Executive with international experience in Biotechnology and Pharma. Management appointments in Large and Mid-Cap US/EU Biopharma companies (Novo Nordisk, ZymoGenetics inc). Proven track record with product approvals, financing, M&A and IPO at Nasdaq (ZGEN) and Euronext (BUP.PA). Incorporated ProFibrix Inc in 2008, and as CEO in 2013 led ProFibrix through $240Mill M&A with The Medicines Company after successful Phase 3 completion and approvals in EU and US. Chairman of the Board at Biomup SA, GTXmedical BV and Blaze Biosciences Inc. M.D from Univ of Copenhagen followed by six years surgical training. Dr Öhrström is a Danish citizen and resident in the Netherlands.
John de KoningMember
Oskar has a broad biotech and business background and is currently partner at BioGeneration Ventures. Oskar started his career in McKinsey & Company as a management consultant. After that he held positions in Crucell, first in business development and later he became responsible for the Pediatric Franchise. After the acquisition of Crucell by Johnson & Johnson, Oskar led the Vaccines & Infectious Diseases business unit in Johnson & Johnson’s pharma joint venture Xian Janssen in Beijing, China. Prior to joining BioGeneration Oskar was Chief Commercial Officer of Avantium, a leading chemical technology company and a forerunner in renewable chemistry.
Oskar has a degree in chemical engineering from Twente University and holds a MBA from INSEAD.
Oskar serves on several boards of companies in BioGeneration’s portfolio.